Table 2.
Risk of venous thrombosis by percentiles of lipid levels
| Patients (n = 2234) |
Controls (n = 2873) |
Pooled control analyses | Partner control analyses | |||
|---|---|---|---|---|---|---|
| OR (95% CI)a | OR (95% CI)b | OR (95%CI)a | OR (95% CI)b | |||
| TC (mmol L−1) | ||||||
| <10th (<4.28) | 217 (10) | 286 (10) | 0.94 (0.78–1.15) | 1.04 (0.84–1.29) | 1.09 (0.80–1.49) | 1.21 (0.87–1.69) |
| 10th–25th (4.28–4.84) | 346 (15) | 428 (15) | 1.02 (0.87–1.21) | 1.06 (0.89–1.26) | 0.87 (0.69–1.11) | 0.98 (0.75–1.27) |
| 25th–75th (4.84–6.30) | 1107 (50) | 1431 (50) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 75th–90th (6.30–7.04) | 332 (15) | 441 (15) | 0.98 (0.83–1.16) | 0.96 (0.81–1.14) | 0.74 (0.59–0.94) | 0.78 (0.61–1.01) |
| >90th (>7.04) | 232 (10) | 287 (10) | 1.07 (0.88–1.29) | 1.00 (0.82–1.22) | 0.80 (0.61–1.06) | 0.82 (0.60–1.11) |
| LDL-C (mmol L−1) | ||||||
| <10th (<2.38) | 213 (10) | 282 (10) | 0.92 (0.76–1.12) | 1.09 (0.88–1.35) | 1.16 (0.85–1.59) | 1.42 (1.01–1.99) |
| 10th–25th (2.38–2.87) | 304 (14) | 425 (15) | 0.88 (0.75–1.04) | 0.97 (0.81–1.15) | 0.98 (0.75–1.26) | 1.05 (0.79–1.39) |
| 25th–75th (2.87–4.17) | 1118 (51) | 1414 (50) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 75th–90th (4.17–4.85) | 342 (15) | 425 (15) | 1.03 (0.87–1.21) | 1.02 (0.86–1.21) | 0.92 (0.73–1.15) | 0.88 (0.68–1.13) |
| >90th (>4.85) | 228 (10) | 282 (10) | 1.05 (0.86–1.27) | 0.98 (0.80–1.20) | 0.93 (0.71–1.22) | 0.96 (0.71–1.29) |
| Triglycerides (mmol L−1) | ||||||
| <10th (<0.79) | 224 (10) | 273 (10) | 1.02 (0.84–1.25) | 1.14 (0.92–1.40) | 1.26 (0.92–1.72) | 1.39 (0.99–1.95) |
| 10th–25th (0.79–1.00) | 309 (14) | 441 (15) | 0.89 (0.75–1.05) | 0.95 (0.80–1.14) | 0.94 (0.73–1.21) | 1.01 (0.77–1.32) |
| 25th–75th (1.00–1.88) | 1104 (49) | 1440 (50) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 75th–90th (1.88–2.58) | 355 (16) | 432 (15) | 1.09 (0.93–1.29) | 1.05 (0.88–1.24) | 1.01 (0.80–1.27) | 0.98 (0.76–1.26) |
| >90th (>2.58) | 242 (11) | 287 (10) | 1.13 (0.93–1.36) | 0.96 (0.79–1.18) | 0.95 (0.72–1.24) | 0.89 (0.66–1.20) |
| Apo B (g L−1) | ||||||
| <10th (<0.68) | 292 (13) | 285 (10) | 1.35 (1.12–1.62) | 1.54 (1.26–1.88) | 1.30 (0.99–1.72) | 1.49 (1.10–2.00) |
| 10th–25th (0.68–0.80) | 356 (16) | 431 (15) | 1.10 (0.93–1.29) | 1.20 (1.01–1.42) | 1.01 (0.79–1.28) | 1.19 (0.92–1.54) |
| 25th–75th (0.80–1.15) | 1071 (48) | 1435 (50) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 75th–90th (1.15–1.33) | 313 (14) | 425 (15) | 1.00 (0.85–1.18) | 0.91 (0.76–1.08) | 0.95 (0.74–1.21) | 1.06 (0.81–1.38) |
| >90th (>1.33) | 202 (9) | 297 (10) | 0.92 (0.75–1.12) | 0.84 (0.68–1.03) | 0.98 (0.73–1.33) | 1.01 (0.73–1.40) |
| HDL-C (mmol L−1) | ||||||
| <10th (<0.90) | 272 (12) | 289 (10) | 1.35 (1.11–1.62) | 1.12 (0.91–1.37) | 1.04 (0.79–1.38) | 0.90 (0.66–1.23) |
| 10th–25th (0.90–1.07) | 387 (17) | 434 (15) | 1.26 (1.07–1.48) | 1.17 (0.99–1.39) | 1.08 (0.85–1.36) | 1.04 (0.81–1.34) |
| 25th–75th (1.07–1.56) | 1068 (48) | 1449 (50) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 75th–90th (1.56–1.86) | 330 (15) | 421 (15) | 1.03 (0.87–1.22) | 1.12 (0.94–1.33) | 1.12 (0.87–1.44) | 1.14 (0.86–1.49) |
| >90th (>1.86) | 177 (8) | 280 (10) | 0.82 (0.67–1.01) | 0.97 (0.78-1.21) | 0.79 (0.58-1.09) | 0.80 (0.57-1.13) |
| Apo A1 (g L−1) | ||||||
| <10th (<1.09) | 322 (14) | 295 (10) | 1.50 (1.25–1.79) | 1.36 (1.12–1.64) | 1.26 (0.97–1.65) | 1.19 (0.89–1.60) |
| 10th–25th (1.09–1.22) | 347 (16) | 429 (15) | 1.09 (0.93–1.29) | 1.02 (0.86–1.21) | 0.98 (0.77–1.24) | 0.91 (0.70–1.18) |
| 25th–75th (1.22–1.59) | 1107 (50) | 1444 (50) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| 75th–90th (1.59–1.81) | 296 (13) | 432 (15) | 0.86 (0.73–1.02) | 0.96 (0.80–1.15) | 0.84 (0.66–1.08) | 0.91 (0.69–1.19) |
| >90th (>1.81) | 162 (7) | 273 (10) | 0.73 (0.59–0.90) | 0.88 (0.70–1.10) | 0.66 (0.47–0.93) | 0.67 (0.47–0.97) |
Data were missing for some participants in some subgroups
OR odds ratio, CI confidence interval, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, Apo B apolipoprotein B, HDL-C high-density lipoprotein cholesterol, Apo A1 apolipoprotein A1
aAdjusted for age, sex and partnership (where applicable)
bAdjusted for age, sex, body mass index, estrogen use at blood sampling, statin use, self-reported diabetes, and partnership (where applicable)
ORb (full adjustment) for apo B and apo A1 is in bold